These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30262796)

  • 41. Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data.
    van Marcke C; Collard A; Vikkula M; Duhoux FP
    Crit Rev Oncol Hematol; 2018 Dec; 132():138-144. PubMed ID: 30447919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
    Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High frequency of pathogenic non-founder germline mutations in
    Maksimenko J; Irmejs A; Trofimovičs G; Bērziņa D; Skuja E; Purkalne G; Miklaševičs E; Gardovskis J
    Hered Cancer Clin Pract; 2018; 16():12. PubMed ID: 29928469
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
    Front Genet; 2021; 12():674094. PubMed ID: 34917121
    [No Abstract]   [Full Text] [Related]  

  • 45. Germline variants of uncertain significance, their frequency, and clinico-pathological features in a cohort of Sri Lankan patients with hereditary breast cancer.
    Gunawardena K; Sirisena ND; Anandagoda G; Neththikumara N; Dissanayake VHW
    BMC Res Notes; 2023 Jun; 16(1):95. PubMed ID: 37277882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population.
    Goidescu IG; Caracostea G; Eniu DT; Stamatian FV
    Clujul Med; 2018; 91(2):157-165. PubMed ID: 29785153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome.
    Ferrer-Avargues R; Castillejo MI; Dámaso E; Díez-Obrero V; Garrigos N; Molina T; Codoñer-Alejos A; Segura Á; Sánchez-Heras AB; Castillejo A; Soto JL
    Cancer Commun (Lond); 2021 Mar; 41(3):218-228. PubMed ID: 33630411
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
    Santonocito C; Scapaticci M; Guarino D; Bartolini A; Minucci A; Concolino P; Scambia G; Paris I; Capoluongo E
    Breast; 2017 Dec; 36():74-78. PubMed ID: 29020660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
    PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid screening test of most frequent BRCA1/BRCA2 pathogenic variants in the NGS era.
    Zidekova D; Waczulikova I; Dolesova L; Vavrova L; Hamidova O; Lohajova Behulova R; Konecny M
    Neoplasma; 2018; 65(2):309-315. PubMed ID: 29534594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Landscape of germline
    Ferreyra Y; Rosas G; Cock-Rada AM; Araujo J; Bravo L; Doimi F; Casas J; Clavo MLÁ; Pinto JA; Belmar-López C
    Front Oncol; 2023; 13():1227864. PubMed ID: 37664050
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Using Co-segregation and Loss of Heterozygosity Analysis to Define the Pathogenicity of Unclassified Variants in Hereditary Breast Cancer Patients.
    Grasel RS; Felicio PS; de Paula AE; Campacci N; Garcia FAO; de Andrade ES; Evangelista AF; Fernandes GC; Sabato CDS; De Marchi P; Souza CP; de Paula CAA; Torrezan GT; Galvão HCR; Carraro DM; Palmero EI
    Front Oncol; 2020; 10():571330. PubMed ID: 33134171
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 58. copy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian cancer.
    Kuusisto KM; Akinrinade O; Vihinen M; Kankuri-Tammilehto M; Laasanen SL; Schleutker J
    PLoS One; 2013; 8(8):e71802. PubMed ID: 23967248
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
    Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
    Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spectrum of High-Risk Mutations among Breast Cancer Patients Referred for Multigene Panel Testing in a Romanian Population.
    Goidescu IG; Nemeti G; Surcel M; Caracostea G; Florian AR; Cruciat G; Staicu A; Muresan D; Goidescu C; Pintican R; Eniu DT
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.